Online citations, reference lists, and bibliographies.
← Back to Search

Acromegaly In The Elderly Patients

M. Ambrosio, I. Gagliardi, S. Chiloiro, A. M. Ferreira, M. Bondanelli, A. Giampietro, A. Bianchi, L. Marinis, M. Fleseriu, M. Zatelli
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background Acromegaly is a rare disease characterized by a chronic exposition to growth hormone (GH) and insulin-like growth factor-1 (IGF-1), caused in most cases by a pituitary GH-secreting adenoma. Chronic GH excess induces systemic complications (metabolic, cardiovascular, respiratory, neoplastic, and musculoskeletal) and increased mortality if not appropriately treated. Recent epidemiological data report an improved life span of patients with acromegaly probably due to better acromegaly management; additionally, the number of pituitary incidentaloma in general population also increased over time due to more frequent imaging. Therefore, the number of elderly patients, newly diagnosed with acromegaly or in follow-up, is expected to grow in the coming years and clinicians will need to be aware of particularities in managing these patients. Purpose This review aims to explore different aspects of acromegaly of the elderly patients, focusing on epidemiology, diagnosis, clinical presentation, complications, and management options. Methods Available literature has been assessed through PubMed (data until August 2019) by specific keywords. Conclusions Available data on acromegaly in the elderly patient are sparse, but point to important differences. Further studies are needed comparing elderly with younger patients with acromegaly to better define a tailored diagnostic and therapeutic management.
This paper references
10.3171/2013.8.JNS13224
Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Derya Burcu Hazer (2013)
10.1210/JCEM.86.7.7635
CLINICAL PERSPECTIVE: Acromegaly and Cancer: Not a Problem?
S. Melmed (2001)
influence of age and sex
A. J. van der Lely (1992)
10.1530/EJE-07-0358
AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.
M. Bex (2007)
10.1210/jc.2007-2084
Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index.
A. M. Arafat (2008)
10.1210/jc.2017-02457
Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature
J. Dal (2018)
10.1007/s11102-018-0873-7
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly
S. Chiloiro (2018)
10.1111/crj.12618
Airway and sleep disorders in patients with acromegaly
O. Turan (2018)
10.1530/EJE.0.1510309
Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly.
B. Herrmann (2004)
10.1016/j.medin.2017.10.003
Systematic review and meta-analysis.
M. Delgado-Rodríguez (2018)
10.1007/s11102-015-0673-2
Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort
C. Sievers (2015)
10.1530/EJE-16-0117
Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.
J. Dal (2016)
a study on 1311 subjects
M. Hein (2017)
10.1210/JC.2005-2110
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients.
A. Colao (2006)
10.1016/j.beem.2019.04.003
The risk/benefit ratio of radiotherapy in pituitary tumors.
G. Minniti (2019)
10.1046/J.1563-2571.2000.200106.X
Diabetes‐Häufigkeit bei Akromegalie und Cushing‐Syndrom
H. Biering (2000)
a claims-based analysis
M. S. Broder (2016)
10.1007/s12020-016-0895-8
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
H. Schmid (2016)
10.1210/jc.2018-01360
Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly
C. Scaroni (2019)
10.1210/jc.2014-2468
A structural and functional acromegaly classification.
D. Cuevas-Ramos (2015)
the French acromegaly registry
L. Maione (2017)
quelles particularités? Pan Afr
N. Anoun (2017)
the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index
A. M. Arafat (2008)
10.1586/eem.11.82
Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment
M. Davi’ (2012)
10.3389/fendo.2019.00120
Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them?
A. Ramos-Leví (2019)
10.1111/cen.12262
FRAX score in acromegaly: does it tell the whole story?
Jessica Brzana (2014)
10.1016/j.wneu.2013.01.021
Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients.
Manouchehr Shirvani (2014)
10.1007/s11102-012-0420-x
A consensus on the diagnosis and treatment of acromegaly complications
S. Melmed (2012)
10.1016/j.wneu.2018.11.024
Safety and Outcome of Transsphenoidal Pituitary Adenoma Resection in Elderly Patients.
Mohammed A. Azab (2019)
10.1007/s007010100015
Surgical Treatment and Clinical Outcome of GH-Secreting Adenomas in Elderly Patients
G. Minniti (2001)
10.1210/JCEM.82.9.4216
Defective hypothalamic growth hormone (GH)-releasing hormone activity may contribute to declining GH secretion with age in man.
E. D. degli Uberti (1997)
10.1182/BLOOD.V126.23.4178.4178
Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients
E. Terpos (2015)
10.1007/s11102-016-0754-x
Epidemiology of acromegaly: review of population studies
Aikaterini Lavrentaki (2016)
10.1007/s12020-018-1630-4
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database
F. Gatto (2018)
10.1016/j.jocd.2012.07.001
Vertebral fracture assessment in acromegaly.
C. Cipriani (2013)
10.1016/j.wneu.2018.06.165
Transsphenoidal Surgery for Elderly Patients with Acromegaly and Its Outcomes: Comparison with Younger Patients.
Y. Sasagawa (2018)
a cohort study and meta-analysis of the literature
J. Dal (2018)
10.1007/BF03345139
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly
S. Grottoli (2003)
10.1530/EJE-18-0255
Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis.
F. Bolfi (2018)
10.1007/s12020-016-1191-3
Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management
A. Ramos-Leví (2016)
10.1530/EJE-16-0178
MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited.
C. Boguszewski (2016)
a randomised, phase 3 trial
M. R. Gadelha (2014)
10.1210/er.2018-00115
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.
M. Gadelha (2019)
10.1227/00006123-199504000-00006
Pituitary surgery in elderly patients with acromegaly.
M. Puchner (1995)
10.3389/fendo.2017.00040
Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
V. Geraedts (2017)
10.1210/JC.2006-1412
Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant.
C. Parkinson (2007)
10.1007/BF03346334
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients
A. Colao (2007)
10.1530/EJE-16-1064
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry.
L. Maione (2017)
10.1007/s11102-018-0924-0
Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey
L. Nachtigall (2018)
Vertebral fractures in patients with Endocrine (2020) 68:16–31 29 acromegaly: a 3-year prospective study
G. Mazziotti (2013)
comparison with younger patients
Y. Sasagawa (2018)
Acromegaly and cancer: not a problem?
S. Melmed (2001)
10.1007/s12020-018-1732-z
Reply to “Predictors of surgical outcome and early criteria of remission in acromegaly—some controversial issues”
Ximene Antunes (2018)
10.1007/s11102-017-0797-7
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities
R. Pivonello (2017)
10.1007/s11102-016-0758-6
Acromegalic osteopathy
G. Mazziotti (2016)
review of population studies
A. Lavrentaki (2017)
A nationwide cohort study
Chia-Chun Tseng (2016)
10.1530/EJE-08-0442
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease.
M. Davi’ (2008)
10.4315/0362-028X-47.2.145
An Update.
K. M. Johnson (1984)
10.1210/jc.2011-0554
Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome.
J. Jane (2011)
10.1046/j.1365-2265.1996.00852.x
Sleep apnoea in treated acromegaly: relative frequency and predisposing factors
F. Rosenow (1996)
10.1530/EJE-12-0147
Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study.
K. M. J. A. Claessen (2012)
tumors : a “ Pituitary Society ” survey
G. Reimondo
10.1210/jc.2019-00825
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study.
S. Chiloiro (2019)
10.1530/EJE-07-0753
Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging.
F. R. V. Van Haute (2008)
10.1016/j.wneu.2018.06.009
Endoscopic Endonasal Approach to the Growth Hormone-Secreting Pituitary Adenomas: Endocrinologic Outcome in 68 Patients.
M. Taghvaei (2018)
10.1007/s12020-018-1797-8
Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature
C. Briet (2018)
10.1530/ERC-17-0253
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
P. Petrossians (2017)
10.1507/ENDOCRJ.K08E-117
Treatment of elderly acromegalics.
K. Arita (2008)
10.1007/s12020-016-1182-4
Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
M. Fleseriu (2016)
The Effect of Endocrine Disorders on Lipids and Lipoproteins
Kenneth K. Feingold (2000)
10.1007/s11102-017-0847-1
Bone histomorphometry in acromegaly patients with fragility vertebral fractures
L. Dalle Carbonare (2017)
10.1210/ER.2002-0022
Systemic complications of acromegaly: epidemiology, pathogenesis, and management.
A. Colao (2004)
10.1159/000022028
Brisk Walking and Postural Stability: A Cross-Sectional Study in Postmenopausal Women
K. Brooke-Wavell (1998)
does it tell the whole story? Clin
J. Brzana (2014)
crossover extension to a randomized, double-blind, phase III study
On behalf of the Pasireotide C2305 Study Group (2016)
cardiovascular, respiratory and metabolic comorbidities
R. Pivonello (2017)
a pituitary society statement
On behalf of The Pituitary Society (2017)
10.1210/jc.2008-2393
Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease.
N. Biermasz (2009)
10.1055/s-0033-1354578
Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly.
H. Sun (2014)
10.1007/BF03343767
Prevalence of the sleep apnea syndrome in acromegaly population
V. Weiss (2000)
The dyslipemic syndrome in acromegaly.
D. Ioaniţiu (1982)
10.1210/JC.2016-2118
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline.
M. Fleseriu (2016)
10.1210/jc.2013-2695
Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study.
K. M. J. A. Claessen (2013)
10.1007/s40618-017-0614-1
Pegvisomant in acromegaly: an update
A. Giustina (2017)
relative frequency and predisposing factors
F. Rosenow (1996)
a comparative crosssectional study
E. Hatipoglu (2015)
10.1007/s11102-013-0471-7
Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients
O. Alexopoulou (2013)
10.1080/17446651.2016.1222899
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly
L. Grasso (2017)
10.1007/s10067-013-2219-1
Functional evaluation of the joints in acromegalic patients and associated factors
Leandro Albuquerque Lemgruber Kropf (2013)
10.1530/EJE.0.1440491
Craniofacial abnormalities and their relevance for sleep apnoea syndrome aetiopathogenesis in acromegaly.
S. Dostálová (2001)
10.1097/MED.0000000000000109
Acromegaly and bone disease
J. Anthony (2014)
no consensus on biochemical parameters
V. J. Geraedts (2017)
remission using modern criteria, complications, and predictors of outcome
J. A. Jane (2011)
a prospective, radiological study
F. Roelfsema (2012)
10.1186/s12931-017-0616-8
Prevalence and risk factors of moderate to severe obstructive sleep apnea syndrome in insomnia sufferers: a study on 1311 subjects
M. Hein (2017)
10.1530/EC-14-0021
Prevalence of diabetes mellitus in patients with acromegaly
A. Dreval (2014)
10.3275/8513
Assessment of sleep apnea syndrome in treated acromegalic patients and correlation of its severity with clinical and laboratory parameters
L. Vannucci (2012)
10.1016/J.RMR.2011.11.017
Caractéristiques du syndrome d’apnées du sommeil dans une cohorte de patients acromégales
M. Chevallier (2012)
Use of electronic health records to characterize a rare disease in the u . s . : treatment , comorbidities , and follow - up trends among patients with a con fi rmed diagnosis of acromegaly
E. D. Roe (1987)
10.11604/PAMJ.2017.27.169.11518
L’acromégalie du sujet âgé: quelles particularités?
Nadia Anoun (2017)
[Prevalence of diabetes in acromegaly and Cushing syndrome].
H. Biering (2000)
10.1530/EJE-10-1005
High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly.
M. J. E. Wassenaar (2011)
10.1210/jc.2017-02566
Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies
A. Cozzolino (2018)
10.1007/s11102-012-0445-1
Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience
Jessica Brzana (2012)
10.1530/EJE.1.02030
Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature.
G. Minniti (2005)
10.1210/jc.2013-1460
Vertebral fractures in patients with acromegaly: a 3-year prospective study.
G. Mazziotti (2013)
a study in 148 patients
O. Alexopoulou (2014)
10.1038/s41574-018-0058-5
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed (2018)
10.1016/j.ghir.2014.12.003
Acromegaly and aging: a comparative cross-sectional study.
E. Hatipoğlu (2015)
10.1007/s12020-017-1391-5
Prevalence of morphometric vertebral fractures in “difficult” patients with acromegaly with different biochemical outcomes after multimodal treatment
S. Chiloiro (2017)
10.1111/j.1365-2265.1992.tb02304.x
The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex
A. J. Lely (1992)
10.1007/BF03345496
Gender- and age-related differences in the endocrine parameters of acromegaly
A. Colao (2002)
10.1111/j.1365-2265.2009.03547.x
Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register
S. Petersenn (2009)
The influence of age on the GH-IGF1 axis in patients with acromegaly
谷本 啓爾 (2009)
pathology and cell biology
M.B.S. Lopes (2010)
10.3171/2010.7.FOCUS10169
Growth hormone-secreting adenomas: pathology and cell biology.
M. Lopes (2010)
10.1186/s12902-016-0096-8
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
M. Bronstein (2016)
10.1007/s12020-018-1660-y
Predictors of surgical outcome and early criteria of remission in acromegaly—some controversial issues
Zihao Wang (2018)
Ioachimescu, Acromegaly and bone disease
A.G.J.R. Anthony (2014)
10.1590/S0100-879X2001001100009
Risk factors for glucose intolerance in active acromegaly.
A. Kréze (2001)
Acromegaly and cancer: an old debate revisited
C. L. Boguszewski (2016)
10.1007/978-3-642-57418-4_11
The Italian survey
M. Bartolomeo (2003)
10.1016/j.wneu.2017.11.043
Postoperative Gamma Knife Radiosurgery for Cavernous Sinus-Invading Growth Hormone-Secreting Pituitary Adenomas.
E. H. Kim (2018)
10.1016/j.rmr.2011.11.017
[Characteristics of sleep apnea syndrome in a cohort of patients with acromegaly].
M. Chevallier (2012)
10.1172/JCI39375
Acromegaly pathogenesis and treatment.
S. Melmed (2009)
10.1007/s40618-018-0928-7
Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy
M. Caputo (2018)
奇形・脳性麻痺の起因に関するprospective follow up studyについて
高井 俊夫 (1966)
10.1530/EJE-12-0084
Predictors of morbidity and mortality in acromegaly: an Italian survey.
M. Arosio (2012)
a survey in Italy
M. Terzolo (2017)
clinical features at diagnosis
L. Vilar (2017)
an update on their diagnosis and management
A. M. Ramos-Leví (2017)
endocrinologic outcome in 68 patients
M. Taghvaei (2018)
10.4158/EP161397.OR
INCIDENCE AND PREVALENCE OF ACROMEGALY IN THE UNITED STATES: A CLAIMS-BASED ANALYSIS.
M. Broder (2016)
10.1007/s12020-014-0383-y
Growth hormone tumor histological subtypes predict response to surgical and medical therapy
Katja Kiseljak-Vassiliades (2014)
10.1210/jc.2018-02281
Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies.
Tiziana Feola (2019)
a large single center experience
J. Brzana (2013)
10.1590/2359-3997000000210
Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response.
L. Kasuki (2016)
10.1016/S2213-8587(14)70169-X
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
M. Gadelha (2014)
10.1007/s11102-016-0772-8
Acromegaly: clinical features at diagnosis
L. Vilar (2016)
10.1007/s12020-012-9660-9
Clinical implications of growth hormone–secreting tumor subtypes
Katja Kiseljak-Vassiliades (2012)
10.1023/A:1020798430884
Pathogenesis and Prevalence of Hypertension in Acromegaly
M. Bondanelli (2004)
10.1157/13125587
Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response.
Y. González-Lama (2008)
10.1007/s11102-017-0838-2
Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
F. F. Casanueva (2017)
10.1111/j.1365-2265.2006.02584.x
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly
A. Colao (2006)
10.1007/978-1-4020-5614-7_2008
Longitudinal Study
M. O'Connor (2013)
10.1007/s11102-015-0701-2
Incidence and prevalence of acromegaly in a large US health plan database
T. Burton (2015)
a review on prevalence, pathogenetic aspects and treatment
M. V. Davì (2012)
10.1007/s12020-019-01959-0
Pituitary adenomas in elderly patients: clinical and surgical outcome analysis in a large series
A. Spina (2019)
10.1007/s12020-019-01874-4
Acromegaly can be cured by first-line pasireotide treatment?
S. Chiloiro (2019)
Tumor Centers of Excellence ( PTCOE ) : a pituitary society statement Growth hormone - secreting adenomas : pathology and cell biology
M. Buchfelder
an MRI study
K.M.J.A. Claessen (2017)
An Endocrine Society Clinical Practice Guideline Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient:
D. Heber (2010)
10.1155/2013/723432
Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification according to Hormone Production and Cytokeratin Distribution
R. Mori (2013)
10.4158/EP-2017-0243
USE OF ELECTRONIC HEALTH RECORDS TO CHARACTERIZE A RARE DISEASE IN THE U.S.: TREATMENT, COMORBIDITIES, AND FOLLOW-UP TRENDS AMONG PATIENTS WITH A CONFIRMED DIAGNOSIS OF ACROMEGALY.
Julie M Silverstein (2018)
epidemiology, pathogenesis, and management
A. Colao (2004)
a 3-year prospective study
G. Mazziotti (2013)
10.1530/EJE-16-1073
Acromegalic arthropathy in various stages of the disease: an MRI study.
K. M. J. A. Claessen (2017)
a “Pituitary Society” survey
L. B. Nachtigall (2019)
10.1007/s11102-010-0284-x
Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism
A. Espinosa-de-los-Monteros (2010)
10.1007/s11102-016-0782-6
Cabergoline in acromegaly
E. Kuhn (2016)
10.1530/EJE-10-1050
Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry.
S. Fieffé (2011)
10.1530/ERC-16-0553
Acromegaly is associated with increased cancer risk: a survey in Italy.
M. Terzolo (2017)
10.1210/jc.2014-2700
Acromegaly: an endocrine society clinical practice guideline.
L. Katznelson (2014)
10.1111/j.1365-2265.2008.03322.x
Spinal volumetric trabecular bone mass in acromegalic patients: a longitudinal study
C. Battista (2009)
10.1210/jc.2013-1581
Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas.
A. Ribeiro-Oliveira (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar